Trials / Completed
CompletedNCT05147181
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
Lanadelumab Treatment Outcomes in HAE Polish Patients Treated in the Scope of National Drug Program (NDP). Prospective, Multicenter Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 48 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to learn about how many persons with HAE type I or type II are attack-free when treated with lanadelumab in real life, how many attacks occur and how many of these attacks need rescue treatment and about the nature of HAE attacks. Participants will need to visit their doctor 5 times in total as part of this study. The visits are planned every 6 months. Participants will also be asked to fill out questionnaires as part of this study.
Conditions
Timeline
- Start date
- 2022-03-11
- Primary completion
- 2025-11-13
- Completion
- 2025-11-13
- First posted
- 2021-12-07
- Last updated
- 2026-03-31
Locations
14 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT05147181. Inclusion in this directory is not an endorsement.